L'Hocine Yahia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
L'Hocine Yahia has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Akier Assanta Mafu
Saint-Hyacinthe Research and Development Centre, Agriculture and Agri-Food Canada, St-Hyacinthe, QC, Canada
1 shared publicationFrançois Gagné-Bourque
Biotechnologies Ulysse, Trois-Rivières, QC, Canada
1 shared publication- Giuseppe Grazzini
University of Florence
1 shared publication - Marie Christine Uwamahoro
Laboratory of Innovation and Analysis of Bioperformance, Ecole Polytechnique de Montreal, Montreal, QC, Canada
1 shared publication - Miroslav Grmela
École Polytechnique Montréal suc. Centre-ville C.P.6079 H3C 3A7 Montréal Québec Canada
1 shared publication - Nancy Tawil
Qeen BioTechnologies, Gatineau, QC J9J 3K3, Canada
1 shared publication
Latest Publications
- Open Access
- 28 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5858
Transdermal Delivery of Cannabidiol for the Management of Acute Inflammatory Pain: A Comprehensive Review of the Literature
The emerging field of nanotechnology has paved the way for revolutionary advancements in drug delivery systems, with nanosystems emerging as a promising avenue for enhancing the therapeutic potential and the stability of various bioactive compounds. Among these, cannabidiol (CBD), the non-psychotropic compound of the Cannabis sativa plant, has gained attention for its therapeutic properties. Consequently, researchers have devoted significant efforts to unlock the full potential of CBD’s clinical benefits, where various nanosystems and excipients have emerged to overcome challenges associated with its bioavailability, stability, and controlled release for its transdermal application. Therefore, this comprehensive review aims to explain CBD’s role in managing acute inflammatory pain and offers an overview of the state of the art of existing delivery systems and excipients for CBD. To summarize this review, a summary of the cannabinoids and therapeutical targets of CBD will be discussed, followed by its conventional modes of administration. The transdermal route of administration and the current topical and transdermal delivery systems will also be reviewed. This review will conclude with an overview of in vivo techniques that allow the evaluation of the anti-inflammatory and analgesic potentials of these systems.
- 28 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5858
Open AccessTransdermal Delivery of Cannabidiol for the Management of Acute Inflammatory Pain: A Comprehensive Review of the Literature
The emerging field of nanotechnology has paved the way for revolutionary advancements in drug delivery systems, with nanosystems emerging as a promising avenue for enhancing the therapeutic potential and the stability of various bioactive compounds. Among these, cannabidiol (CBD), the non-psychotropic compound of the Cannabis sativa plant, has gained attention for its therapeutic properties. Consequently, researchers have devoted significant efforts to unlock the full potential of CBD’s clinical benefits, where various nanosystems and excipients have emerged to overcome challenges associated with its bioavailability, stability, and controlled release for its transdermal application. Therefore, this comprehensive review aims to explain CBD’s role in managing acute inflammatory pain and offers an overview of the state of the art of existing delivery systems and excipients for CBD. To summarize this review, a summary of the cannabinoids and therapeutical targets of CBD will be discussed, followed by its conventional modes of administration. The transdermal route of administration and the current topical and transdermal delivery systems will also be reviewed. This review will conclude with an overview of in vivo techniques that allow the evaluation of the anti-inflammatory and analgesic potentials of these systems.
- Open Access
- 5 February 2018
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 6, 18
Evaluating the Sporicidal Activity of Disinfectants against Clostridium difficile and Bacillus amyloliquefaciens Spores by Using the Improved Methods Based on ASTM E2197-11
Spore-forming pathogenic bacteria, such as Clostridium difficile, are associated with nosocomial infection, leading to the increased use of sporicidal disinfectants, which impacts socioeconomic costs. However, C. difficile can be prevented using microorganisms such as Bacillus amyloliquefaciens, a prophylactic agent that has been proven to be effective against it in recent tests or it can be controlled by sporicidal disinfectants. These disinfectants against spores should be evaluated according to a known and recommended standard. Unfortunately, some newly manufactured disinfectants like Bioxy products have not yet been tested. ASTM E2197-11 is a standard test that uses stainless steel disks (1 cm in diameter) as carriers, and the performance of the test formulation is calculated by comparing the number of viable test organisms to that on the control carriers. Surface tests are preferable for evaluating disinfectants with sporicidal effects on hard surfaces. This study applies improved methods, based on the ASTM E2197-11 standard, for evaluating and comparing the sporicidal efficacies of several disinfectants against spores of C. difficile and B. amyloliquefaciens, which are used as the test organisms. With the improved method, all spores were recovered through vortexing and membrane filtration. The results show that chlorine-based products are effective in 5 min and Bioxy products at 5% w/v are effective in 10 min. Although Bioxy products may take longer to prove their effectiveness, their non-harmful effects to hospital surfaces and people have been well established in the literature.
- 5 February 2018
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 6, 18
Open AccessEvaluating the Sporicidal Activity of Disinfectants against Clostridium difficile and Bacillus amyloliquefaciens Spores by Using the Improved Methods Based on ASTM E2197-11
Spore-forming pathogenic bacteria, such as Clostridium difficile, are associated with nosocomial infection, leading to the increased use of sporicidal disinfectants, which impacts socioeconomic costs. However, C. difficile can be prevented using microorganisms such as Bacillus amyloliquefaciens, a prophylactic agent that has been proven to be effective against it in recent tests or it can be controlled by sporicidal disinfectants. These disinfectants against spores should be evaluated according to a known and recommended standard. Unfortunately, some newly manufactured disinfectants like Bioxy products have not yet been tested. ASTM E2197-11 is a standard test that uses stainless steel disks (1 cm in diameter) as carriers, and the performance of the test formulation is calculated by comparing the number of viable test organisms to that on the control carriers. Surface tests are preferable for evaluating disinfectants with sporicidal effects on hard surfaces. This study applies improved methods, based on the ASTM E2197-11 standard, for evaluating and comparing the sporicidal efficacies of several disinfectants against spores of C. difficile and B. amyloliquefaciens, which are used as the test organisms. With the improved method, all spores were recovered through vortexing and membrane filtration. The results show that chlorine-based products are effective in 5 min and Bioxy products at 5% w/v are effective in 10 min. Although Bioxy products may take longer to prove their effectiveness, their non-harmful effects to hospital surfaces and people have been well established in the literature.
- Open Access
Multiscale Mesoscopic Entropy of Driven Macroscopic Systems
How do macroscopic systems react to imposed external forces? Attempts to answer this question by a general principle have a long history. The general feeling is that the macroscopic systems in their reaction to imposed external forces follow some kind of optimization strategy in which their internal structure is changed so that they offer the least possible resistance. What is the potential involved in such optimization? It is often suggested that it is entropy or entropy production. But entropy is a potential arising in thermodynamics of externally unforced macroscopic systems. What exactly shall we understand by a mesoscopic entropy of externally driven systems and how shall we find it for a specific macroscopic system?
Open AccessMultiscale Mesoscopic Entropy of Driven Macroscopic Systems
How do macroscopic systems react to imposed external forces? Attempts to answer this question by a general principle have a long history. The general feeling is that the macroscopic systems in their reaction to imposed external forces follow some kind of optimization strategy in which their internal structure is changed so that they offer the least possible resistance. What is the potential involved in such optimization? It is often suggested that it is entropy or entropy production. But entropy is a potential arising in thermodynamics of externally unforced macroscopic systems. What exactly shall we understand by a mesoscopic entropy of externally driven systems and how shall we find it for a specific macroscopic system?